-
公开(公告)号:US20220218838A1
公开(公告)日:2022-07-14
申请号:US17609129
申请日:2020-05-06
IPC分类号: A61K47/68 , A61P35/00 , A61K47/54 , A61K31/704 , A61K31/675 , A61K31/7068 , A61K33/243 , A61K31/337 , A61K31/506 , A61K31/282 , A61K31/513 , A61K31/65 , A61K31/4184
摘要: The present invention relates to an ADC having the following formula (I) in which Ab is an anti-IGF1R antibody characterized in that it comprises light chain CDRs of sequences SEQ ID Nos. 9, 5 and 11, respectively, and heavy chain CDRs of sequences SEQ ID Nos. 7, 2 and 3, respectively, and n is between 1 and 12, for use in the treatment of proliferative diseases, such as cancer, characterized in that the ADC is administered concomitantly with or subsequent to docetaxel.
-
公开(公告)号:US20220071860A1
公开(公告)日:2022-03-10
申请号:US17415875
申请日:2019-12-19
摘要: The subject matter of the present invention is a novel composition in emulsion form comprising glycerol, vaseline, and liquid paraffin as well as a particular system of preservatives and gelling agents, wherein said composition is characterised by the absence of parabens.
-
3.
公开(公告)号:US10881702B2
公开(公告)日:2021-01-05
申请号:US15998967
申请日:2017-02-17
发明人: Thien Nguyen , Arnaud Pillon
IPC分类号: A61K36/37 , A61P35/00 , A61K31/122 , A61K31/215
摘要: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
-
公开(公告)号:US20200270352A1
公开(公告)日:2020-08-27
申请号:US16801491
申请日:2020-02-26
发明人: Ian RILATT , Michel PEREZ , Liliane GOETSCH , Matthieu BROUSSAS , Charlotte BEAU-LARVOR , Jean-Francois HAEUW , Thierry CHAMPION , Alain ROBERT , Marie LAMOTHE
摘要: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
-
公开(公告)号:US20200040102A1
公开(公告)日:2020-02-06
申请号:US16519411
申请日:2019-07-23
摘要: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
-
公开(公告)号:US10548885B2
公开(公告)日:2020-02-04
申请号:US15310415
申请日:2015-07-09
IPC分类号: A61K31/4545 , A61K9/00 , A61K47/38
摘要: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
-
公开(公告)号:US10265322B2
公开(公告)日:2019-04-23
申请号:US15962837
申请日:2018-04-25
IPC分类号: A61K31/495 , A61K31/5377 , A61K31/443 , A61P13/10 , A61P13/00
摘要: The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.
-
公开(公告)号:US20190062339A1
公开(公告)日:2019-02-28
申请号:US15765048
申请日:2016-10-03
IPC分类号: C07D491/22 , C07D519/00 , A61P35/00
摘要: The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer.
-
公开(公告)号:US20180222858A1
公开(公告)日:2018-08-09
申请号:US15708685
申请日:2017-09-19
发明人: Michel PEREZ , Ian RILATT , Marie LAMOTHE
IPC分类号: C07D207/09 , A61K38/07 , C07K7/02 , A61K38/05 , C07K5/062 , A61K38/08 , C07D401/12 , C07D417/12 , C07D417/14 , C07D207/08 , C07K5/02 , A61K45/06 , A61K31/175 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/24
CPC分类号: C07D207/09 , A61K31/175 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/24 , A61K38/05 , A61K38/07 , A61K38/08 , A61K45/06 , C07D207/08 , C07D401/12 , C07D417/12 , C07D417/14 , C07K5/0205 , C07K5/06043 , C07K7/02 , A61K2300/00
摘要: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ▪a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ▪—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ▪an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ▪a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
-
公开(公告)号:US20180140609A1
公开(公告)日:2018-05-24
申请号:US15568085
申请日:2016-04-20
发明人: Marie LAMOTHE , Didier JUNQUERO , Bruno LE GRAND
IPC分类号: A61K31/5415
CPC分类号: A61K31/5415 , A61K45/06
摘要: The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2H-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.
-
-
-
-
-
-
-
-
-